UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
UBS analyst Michael Yee called Novo Nordisk a value trap, but still sees a turnaround playing out over time.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.